Loading...
•
Dec 31, 2020
Altimmune Q4 2020 Earnings Report
Announced financial results for Q4 2020 and provided a corporate update.
Key Takeaways
Altimmune reported a net loss of $49.0 million for the year ended December 31, 2020. The company's cash, cash equivalents, and short-term investments totaled $216.0 million at year-end. The company has made substantial progress in each of their five portfolio programs.
Enrollment in the Phase 1 AdCOVID™ Clinical Trial has commenced.
Development of AdCOVID vectors targeting emerging variants of the SARS-CoV-2 Virus has begun.
ALT-801 is progressing through the Phase 1 Clinical Trial.
The company is solidly capitalized to advance pipeline candidates with $216 million in cash and short-term investments at year-end.
Forward Guidance
The company anticipates multiple data readouts from their programs over the coming months and believes 2021 has the potential to be a momentous year.
Positive Outlook
- Data read-out for Phase 1 clinical trial of AdCOVID in Q2 2021
- Data readout from T-COVID trial in Q2 2021
- Data read-out from Phase 1 clinical study for ALT-801 in Q1 2021
- Plan to file an IND application for ALT-801 in mid-2021
- Data read-out from Phase 2 clinical trial of HepTcell in 1H 2022
Challenges Ahead
- Potential impacts due to the COVID-19 pandemic such as delays in regulatory review.
- Manufacturing and supply chain interruptions.
- Adverse effects on healthcare systems and disruption of the global economy.
- The reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...